Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China

Abstract

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) and it could be used as a second-line treatment for patients with chronic myeloid leukemia (CML). Yinishu, a generic dasatinib made in China, was approved by the China Food and Drug Administration in 2013 and it costs much less than the patented dasatinib SPRYCEL. The present study aimed to examine the efficacy and safety of Yinishu as a second-line treatment for CML by comparing the baseline clinical characteristics, rates of adverse events and efficacy between Yinishu and SPRYCEL groups. The results showed that there were no significant differences in the rates of optimal response between Yinishu and SPRYCEL for patients who started second-line treatment because of treatment failure. For patients who started second-line treatment because of intolerance of first-line treatment, their levels of BCR-ABL1/ABL1 on the international scale (BCR-ABL^IS) was maintained very low throughout the course of Yinishu treatment. Drug-related adverse events occurred with the same frequency in these two groups. It was confirmed that Yinishu was effective and safe as a secondline treatment for CML patients. Yinishu may be more suitable for patients who are economically unable to pay for the patented dasatinib SPRYCEL.

Keywords

chronic myeloid leukemia / generic dasatinib / second-line treatment efficacy / safety

References

[1] DeiningerM, O'BrienSG, GuilhotF, et al.. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 2009, 114: 1126

[2] KantarjianH, O'BrienS, JabbourE, et al.. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119(9): 1981-1987

[3] KantarjianHM, ShahNP, CortesJE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012, 119(5): 1123-1129

[4] CortesJE, SaglioG, BaccaraniM, et al.. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood, 2014, 124: 152

[5] BrummendorfTH, CortesJ D S, et al.. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol, 2015, 168(1): 69-81

[6] WangJ, ShenZX, SaglioG, et al.. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood, 2015, 125(18): 2771-2778

[7] HahnEA, GlendenningGA, SorensenMV, et al.. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol, 2003, 21(11): 2138-2146

[8] NoensL, van LierdeMA, De BockR, et al.. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 2009, 113(22): 5401-5411

[9] IbrahimAR, EliassonL, ApperleyJF, et al.. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011, 117(14): 3733-3736

[10] AbboudC, BermanE, CohenA, et al.. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013, 121(22): 4439-4442

[11] DusetzinaSB, WinnAN, AbelGA, et al.. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol, 2013, 32(4): 306-311

[12] SmithAG, PainterD, HowellDA, et al.. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open, 2014, 4(1): e004266

[13] JiangQ, ZhaoD, JinJ, et al.. A prospective, multicentre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2015, 36(8): 651-655

[14] JiangCF, LuoF, LinSS, et al.. Treatment of domestic imatinib Mesylate on 36 patients with Ph positivechronic myeloid leukemia. J Clin Hematol (China), 2016, 29(9): 757-759

[15] LvJL, ChenYP, XiaoQ, et al.. Curative effect and safety analysis of 47 patients with chronic myeloid leukemia after imatinib Mesylate treatment. J Clin Hematol (China), 2016, 29(3): 222-225

[16] KongJ, FuHX, LaiYH, et al.. Dasatinib of china Tai-tianqing as second line treatment for chronic myelogenous leukemia in chronic phase. J Clin Hematol (Chinese), 2016, 29(11): 898-901

[17] MinH, KaifengY, XiaomingL, et al.. Clinical effect of imatinib, nero imatinib and dasatinib on chronic myeloid leukemia in chronic phase. Chin J Clin Pharmacol, 2016, 32(6): 511-513

[18] WangJX. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition). Zhonghua Xue Ye Xue Za Zhi (Chinese), 2016, 37(8): 633-639

[19] TanPF, TanH, LuoXD. A case of chronic myeloid leukemia treated with dasatinib. J Clin Hematol (Chinese), 2016, 29(1): 69-70

[20] FerdinandR, MitchellSA, BatsonS, et al.. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med, 2012, 3: 51-76

[21] ShahNP, KantarjianHM, KimDW, et al.. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 2008, 26(19): 3204-3212